SCHEMBL15935405

SCHEMBL15935405

Cc1cc(C)n(C2CC2)n1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
KDM5A P29375 1/20 0.41
DRD2 P14416 2/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 3/20 0.38
GLA P06280 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTR2A P28223 1/20 0.37
HRH1 P35367 1/20 0.37
GAA P10253 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
GLS O94925 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP1 O94782 2/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748795 0.91 KDM4E (0.46) SMN1; SMN2KDM5ADRD2DRD4DRD3
SCHEMBL31462462 0.90 ALDH1A1 (0.49) SMN1; SMN2KDM5AALDH1A1KDM4EHSD17B10
SCHEMBL3364096 0.90 ALDH1A1 (0.49) SMN1; SMN2KDM5AALDH1A1KDM4EHSD17B10
SCHEMBL28720539 0.88 SMN1; SMN2 (0.38) SMN1; SMN2KDM5ADRD2DRD4DRD3
SCHEMBL28862386 0.87 PDE7A (0.36) SMN1; SMN2KDM5ADRD2DRD4DRD3
SCHEMBL15832226 0.86 SIGMAR1 (0.43) SMN1; SMN2KDM5ADRD2ALDH1A1KDM4E
SCHEMBL2852441 0.86 MEN1 (0.46) SMN1; SMN2KDM5AALDH1A1MEN1KMT2A
SCHEMBL13135665 0.86 ALOX15 (0.51) SMN1; SMN2KDM5ADRD2DRD4DRD3
SCHEMBL18865799 0.86 USP1 (0.37) SMN1; SMN2KDM5ADRD2DRD4DRD3
SCHEMBL18865486 0.86 PDE7A (0.37) SMN1; SMN2KDM5ADRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023001061-A1 CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS JINGRUI BIOPHARMA CO., LTD. (CN) 2023-01-26 WO disclosed
WO-2022261524-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2, COMPOSITION AND APPLICATION THEREOF ACCRO BIOSCIENCE (HK) LIMITED (CN) 2022-12-15 WO disclosed
EP-2934538-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2021-03-31 EP disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 SMN1; SMN2 2530/4885KDM5A 2282/4885DRD2 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.